| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
92,610,000 |
| Market
Cap: |
2.16(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.07 - $31.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,355,932 |
| Total Buy Value |
$0 |
$0 |
$0 |
$19,999,997 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
418,173 |
438,811 |
467,219 |
487,632 |
| Total Sell Value |
$11,574,225 |
$12,042,227 |
$12,602,151 |
$12,990,263 |
| Total People Sold |
7 |
7 |
7 |
8 |
| Total Sell Transactions |
12 |
14 |
24 |
29 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yalamanchi Naveen |
|
• • • |
2018-12-28 |
4 |
A |
$13.93 |
$1,393,000 |
I/I |
100,000 |
16,507,319 |
|
- |
|
| Patel Kinnari |
Chief Operating Officer |
• • – |
2018-12-20 |
4 |
OE |
$1.21 |
$67,601 |
D/D |
55,869 |
55,869 |
|
- |
|
| Southwell David P |
|
• • – |
2018-12-13 |
4 |
S |
$15.19 |
$588,886 |
D/D |
(38,768) |
95,160 |
|
- |
|
| Southwell David P |
|
• • – |
2018-12-07 |
4 |
S |
$14.91 |
$73,402 |
D/D |
(4,923) |
133,928 |
|
- |
|
| Patel Kinnari |
Chief Operating Officer |
• • – |
2018-12-06 |
4 |
B |
$14.98 |
$85,012 |
I/I |
5,675 |
5,675 |
0.01 |
- |
|
| Southwell David P |
|
• • – |
2018-12-06 |
4 |
S |
$15.15 |
$800,056 |
D/D |
(52,809) |
138,851 |
|
- |
|
| Southwell David P |
|
• • – |
2018-11-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
153,125 |
191,660 |
|
- |
|
| Yalamanchi Naveen |
|
• • • |
2018-11-27 |
4 |
A |
$15.50 |
$15,000,001 |
I/I |
967,742 |
16,407,319 |
|
- |
|
| Yalamanchi Naveen |
|
• • – |
2018-08-01 |
4 |
AS |
$22.00 |
$14,014 |
I/I |
(637) |
113,641 |
|
- |
|
| Southwell David P |
Director |
– • – |
2018-04-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,875 |
38,535 |
|
- |
|
| Ritter Dale |
Vice President, Finance |
• – – |
2017-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
19,827 |
|
- |
|
| Southwell David P |
President and CEO |
• • – |
2017-01-06 |
4 |
B |
$1.75 |
$105,000 |
D/D |
60,000 |
62,765 |
2.81 |
- |
|
| Devon Park Associates, Llc |
10% Owner |
– – • |
2017-01-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,253,566) |
0 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2016-05-13 |
4 |
B |
$9.03 |
$90,294 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Rho Ventures Iv-A, L.p. |
10% Owner |
– – • |
2015-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(242,794) |
0 |
|
- |
|
| Kantesaria Devang |
10% Owner |
– – • |
2015-07-14 |
4 |
OE |
$4.34 |
$42,799 |
D/D |
9,857 |
3,253,566 |
|
- |
|
| Pitango G.c. Capital Holdings Ltd. |
10% Owner |
– – • |
2015-02-23 |
4 |
B |
$6.00 |
$1,274,250 |
I/I |
212,375 |
1,292,584 |
1.5 |
- |
|
| Pitango G.c. Capital Holdings Ltd. |
10% Owner |
– – • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
885,567 |
1,080,209 |
|
- |
|
| Care Capital Offshore Investments Iii Lp |
10% Owner |
– – • |
2015-02-23 |
4 |
B |
$6.00 |
$3,622,992 |
I/I |
603,832 |
2,277,139 |
1.5 |
- |
|
| Care Capital Offshore Investments Iii Lp |
10% Owner |
– – • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,458,205 |
1,673,307 |
|
- |
|
| Leschly Mark |
10% Owner |
– – • |
2015-02-23 |
4 |
B |
$6.00 |
$5,749,356 |
I/I |
958,226 |
2,870,584 |
1.5 |
- |
|
| Leschly Mark |
10% Owner |
– – • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,679,322 |
1,912,358 |
|
- |
|
| Karabelas Argeris N |
Director |
– • • |
2015-02-23 |
4 |
B |
$6.00 |
$3,622,992 |
I/I |
603,832 |
2,277,139 |
2.25 |
- |
|
| Karabelas Argeris N |
Director |
– • • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,458,205 |
1,673,307 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2015-02-23 |
4 |
B |
$6.00 |
$2,500,002 |
I/I |
416,667 |
1,917,906 |
1.5 |
- |
|
135 Records found
|
|
Page 5 of 6 |
|
|
0.16 (0.69%) 
